TargetCancer Foundation is a Cambridge-based rare cancer research and patient support foundation, founded by Cambridge resident and 1997 Boston Marathon finisher Paul Poth, after his diagnosis with cholangiocarcinoma at age 37. Since being founded, TCF has invested millions of dollars in driving innovative rare cancer research while developing comprehensive programs to provide patients with personalized treatment data and guidance.
Funds raised through the 2024 Bank of America Boston Marathon Official Charity Program will provide critical real time support for TargetCancer Foundation’s varied rare cancer research and advocacy programs. This includes our efforts to drive innovative research into rare cancers forward, and to provide guidance and support to patients as they navigate the unique challenges of a rare cancer diagnosis.
Team TCF runners are supported in numerous ways throughout their marathon journey. We work with each runner to help them plan their fundraising outreach and events, and we continue to provide support throughout their fundraising campaign. We work with a certified RRCA long-distance coach to provide personalized training plans for team members, and coordinate team training runs where possible. Runner camaraderie is an important component of our team, and we encourage and facilitate this starting at our first team meeting.
We are incredibly proud of our teams over the past nine years who have raised almost $500,000 for critical research and advocacy efforts for the rare cancer community. We look forward to working with this year’s runners as they train and run from Hopkinton to Boylston Street!
You can also support TCF if you are an officially qualified runner for the 2024 Marathon- contact us to learn more.